BofA raised the firm’s price target on BridgeBio (BBIO) to $45 from $42 and keeps a Buy rating on the shares after the company announced the FDA approved its stabilizer acoramidis as Attruby for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback